<DOC>
	<DOCNO>NCT01093859</DOCNO>
	<brief_summary>Exploratory phase 1 , first human , open label , non-randomized , single-dose study PRX-105 , administer intravenously slow bolus injection 10 healthy volunteer . The objective evaluate pharmacokinetic profile PRX-105 without significant physiological effect healthy volunteer single , intravenous microdose administration .</brief_summary>
	<brief_title>An Exploratory Phase 1 Microdose Study PRX-105</brief_title>
	<detailed_description />
	<criteria>Healthy male volunteer age 1845 ( inclusive ) year . Body Mass Index ( BMI ) 19 29 kg/m2 ( inclusive ) weigh least 60 Kg 90 kg . Nonsmoking ( declaration ) period least 6 month prior screen visit . Blood pressure heart rate within normal limit . Electrocardiogram ( ECG ) clinically significant abnormality . History significant neurological ( include history seizure EEG abnormality ) , renal , cardiovascular ( include know structural cardiac abnormality hypertension ) , respiratory ( asthma ) , endocrinological , gastrointestinal , hematopoietic disease , neoplasm , psychological ( marked anxiety , tension agitation ) clinically significant medical disorder , investigator 's judgment contraindicate administration study medication . Current / previous occupational exposure organophosphates pesticide . Previous receipt investigational butyrylcholinesterase product .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>acetylcholinesterase</keyword>
</DOC>